Norges Bank Relmada Therapeutics, Inc. Transaction History

Norges Bank

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$2.48 - $3.79 $136,152 - $208,071	-54,900 Closed	0 $0
Q2 2023 Aug 14, 2023	SELL	$2.22 - $3.54 $125,874 - $200,718	-56,700 Closed	0 $0
Q3 2022 Nov 13, 2023	BUY	$18.3 - $37.02 $1 Million - $2.03 Million	54,900 New	54,900 $2.03 Million
Q2 2022 Aug 14, 2023	BUY	$16.5 - $30.34 $935,550 - $1.72 Million	56,700 New	56,700 $1.08 Million
Q1 2022 May 09, 2022	SELL	$16.72 - $26.99 $1.65 Million - $2.66 Million	-98,500 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$16.93 - $26.82 $1.67 Million - $2.64 Million	98,500 New	98,500 $2.22 Million
Q3 2021 Nov 14, 2022	BUY	$21.86 - $34.77 $2.15 Million - $3.42 Million	98,500 New	98,500 $2.58 Million

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.3M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.